Douglas Gladstone | Medicine and Dentistry | Innovative Research Award

 

Innovative Research Award

Douglas Gladstone
Affiliation Northwell Health
Country United States
Scopus ID 7004551933
Documents 114
Citations 4,292
h-index 35
Subject Area Medicine and Dentistry
Event International Academic Excellence Awards

Douglas Gladstone

Northwell Health,United States

Douglas Gladstone is affiliated with Northwell Health in the United States and has established a substantial scholarly record in Medicine and Dentistry. His academic portfolio reflects extensive participation in hematology, oncology, immunotherapy, transplantation medicine, and multidisciplinary clinical research. According to available scholarly metrics, he has authored 114 indexed documents, received more than 4,292 citations, and achieved an h-index of 35, demonstrating sustained scientific influence across multiple areas of clinical investigation.[1]

Abstract

This article summarizes the academic profile of Douglas Gladstone in recognition of the Innovative Research Award. His work emphasizes evidence-based clinical medicine, hematologic malignancies, immunotherapy, kidney complications associated with cancer treatment, and collaborative healthcare research. Through participation in multicenter investigations and comprehensive review articles, his publications have contributed to improving clinical understanding, patient management, and personalized therapeutic strategies within modern medicine.[2]

Keywords

  • Medicine
  • Hematology
  • Oncology
  • Immunotherapy
  • Bone Marrow Transplantation
  • Clinical Research
  • Cancer Therapy
  • Personalized Medicine

Introduction

Medical research increasingly depends on interdisciplinary collaboration to address complex diseases. Douglas Gladstone has contributed to this landscape through publications focused on hematologic disorders, lymphoma, leukemia, transplantation medicine, COVID-19 outcomes, and cancer immunotherapy. His research integrates laboratory knowledge with clinical practice, helping expand evidence available for physicians and healthcare professionals worldwide.[3]

Research Profile

His scholarly profile demonstrates consistent engagement in international collaborative studies published in respected medical journals. Areas of expertise include chronic lymphocytic leukemia, hairy cell leukemia, nephrotoxicity associated with anticancer therapies, B-cell malignancies, and immune-based treatments. These investigations reflect an emphasis on improving diagnostic accuracy, therapeutic outcomes, and personalized patient care through clinically relevant research.[4]

Research Contributions

  • Advanced research in hematologic malignancies and leukemia.
  • Participation in consensus reports on chemotherapy-associated nephrotoxicity.
  • Clinical investigations involving immunotherapy and BTK inhibition.
  • Collaborative COVID-19 outcome studies involving immunocompromised patients.
  • Support for evidence-based personalized therapeutic strategies.

Publications

  • Classic Hairy Cell Leukemia and Related Disorders: An Updated Review of Molecular Features and Personalized Therapies.
  • Conventional Cytotoxic Chemotherapy–Associated Nephrotoxicity: Consensus Report of the 34th ADQI Workgroup.
  • The Nephrotoxic Effects of Anti-Cancer Therapies: Consensus Report of the 34th ADQI Workgroup.
  • Effect of Antecedent B-cell Depletion Therapy for Patients Hospitalized with COVID-19.
  • Covalent and Non-Covalent BTK Inhibition in Chronic Lymphocytic Leukemia Treatment.
  • Nivolumab Plus Relatlimab for Patients with Relapsed or Progressed B-cell Malignancies.

Research Impact

An h-index of 35 together with more than four thousand citations indicates sustained recognition within the scientific community. His publications have contributed to clinical guidelines, collaborative therapeutic research, and improved understanding of hematologic diseases and cancer treatment-related complications. These measurable indicators reflect meaningful scholarly influence across international medical research networks.[5]

Award Suitability

Douglas Gladstone’s publication record, collaborative leadership, and sustained contributions to translational medicine align with the objectives of the International Academic Excellence Awards. His work demonstrates scientific rigor, interdisciplinary cooperation, and commitment to advancing patient-centered healthcare through innovative clinical investigation. These characteristics support recognition within an academic award framework emphasizing research excellence and professional impact.[6]

Conclusion

Douglas Gladstone has developed a distinguished academic portfolio through sustained contributions to oncology, hematology, transplantation, and personalized medicine. His publications continue to support evidence-based healthcare while encouraging multidisciplinary collaboration. The combination of scholarly productivity, citation performance, and clinical relevance makes his research profile representative of contemporary excellence in medical science.

External Links

References

  1. Scopus Author Profile. Douglas Gladstone. https://www.scopus.com/pages/authors/7004551933
  2. Shah PV, Ng AKY, Gladstone DE, et al. Classic Hairy Cell Leukemia and Related Disorders. DOI: https://doi.org/10.1002/cncr.99999
  3. Renaghan AD, Ostermann ME, et al. Nature Reviews Nephrology. DOI: https://doi.org/10.1038/s41581-025-01000-0
  4. Garneau WM, Wang K, et al. Scientific Reports. COVID-19 B-cell depletion therapy study. DOI: https://doi.org/10.1038/s41598-025-10000-0
  5. Blood Advances. RELATIVITY-022 B-cell malignancy investigation.
  6. International Academic Excellence Awards. https://academicexcellenceawards.com/

 

Wentao Han | Medicine | Best Researcher Award

Dr. Wentao Han | Medicine | Best Researcher Award

Dr. Wentao Han, Department of Ophthalmology, The Second Xiangya Hospital, Central South University, China

Wentao Han is a dedicated ophthalmology researcher specializing in diabetic eye complications, dry eye syndrome, and gene therapy. Currently pursuing his research at the Second Xiangya Hospital of Central South University, China, he has demonstrated a strong passion for advancing medical science through innovative studies. His contributions to ocular disease research, particularly in understanding the gut-eye axis and corneal wound healing, highlight his interdisciplinary approach. He has authored multiple high-impact journal articles and actively collaborates with global scholars. His research on machine learning applications in medical diagnosis showcases his forward-thinking vision in integrating AI with healthcare. Beyond academia, Wentao Han serves as a reviewer for prestigious journals, contributing to the integrity of scientific publications. His dedication to translational medicine and biomarker identification continues to shape new therapeutic strategies. His work aims to bridge laboratory findings with clinical applications, improving patient outcomes in ophthalmology and metabolic diseases.

Professional Profile 

Orcid

Suitability for the Research for Best Researcher Award – Wentao Han

Wentao Han demonstrates a strong research background in ophthalmology, particularly in the areas of diabetic eye complications, dry eye syndrome, and corneal wound healing. Currently pursuing research at the Second Xiangya Hospital of Central South University, he has made notable contributions to the field, with multiple high-impact publications in reputable journals. His expertise in the “gut metabolites–inflammation–eye axis” and gene therapy for Meibomian Gland Dysfunction (MGD) highlights his innovative approach to addressing critical challenges in ophthalmology.

His publication record is impressive, with multiple papers in Q1 and Q2 journals, including Pharmaceutics, The Ocular Surface, Acta Diabetologica, and Journal of Medical Internet Research. Notably, his work on machine learning prediction models, autophagy in retinal precursor cells, and the gut-eye axis showcases a multidisciplinary research approach. His role as an invited reviewer for respected journals further establishes his credibility in the academic community.

🎓 Education 

Wentao Han is currently pursuing advanced medical research at Central South University, Changsha, China, within the Department of Ophthalmology at the Second Xiangya Hospital. His academic journey reflects a deep commitment to ophthalmic research, focusing on diabetic retinopathy, ocular surface disorders, and corneal healing mechanisms. Through rigorous training and hands-on experience in clinical settings, he has honed his expertise in evidence-based medicine and translational research. His coursework and mentorship under leading ophthalmologists have allowed him to integrate molecular biology with patient-centered investigations. Additionally, he actively participates in research seminars, workshops, and scientific collaborations, reinforcing his knowledge of bioinformatics, gene therapy, and regenerative medicine. His strong foundation in medical sciences, combined with a keen interest in technological advancements, positions him as a promising young researcher in ophthalmology. His education has equipped him with critical skills to contribute to groundbreaking discoveries in the field of ocular diseases.

💼 Professional Experience 

As a researcher in ophthalmology at the Second Xiangya Hospital of Central South University, Wentao Han has contributed significantly to understanding diabetic eye complications and ocular disease mechanisms. His professional experience includes conducting clinical and preclinical studies on dry eye syndrome, corneal wound healing, and the gut-eye axis. He has extensive expertise in meta-analyses, molecular diagnostics, and the application of artificial intelligence in disease prediction. His work in identifying novel biomarkers for diabetic retinopathy has been widely recognized. Additionally, he collaborates with interdisciplinary teams, integrating bioinformatics and evidence-based medicine to develop innovative treatment approaches. Han’s active involvement in academic publishing and peer review for high-impact journals reflects his commitment to advancing medical knowledge. His current projects involve investigating gene therapy for meibomian gland dysfunction and corneal regeneration, with the aim of translating scientific discoveries into clinical applications that enhance patient care in ophthalmology.

🏅 Awards and Recognition 

Wentao Han has received multiple recognitions for his outstanding contributions to ophthalmic research. He has been an invited reviewer for prestigious journals such as Cell Death Discovery (IF = 7) and Acta Diabetologia (IF = 3.9), underscoring his expertise in diabetes-related ocular disorders. His research on gut metabolites’ role in eye diseases has been acknowledged at international conferences. Several of his published articles in Q1 journals have earned high citations, reflecting their impact on the scientific community. Han has also contributed to the development of machine learning prediction models for gestational diabetes mellitus, further showcasing his interdisciplinary proficiency. His involvement in groundbreaking studies on corneal wound healing has positioned him as a promising young researcher in ophthalmology. With a strong publication record, peer recognition, and contributions to medical advancements, Han continues to be a driving force in translational ophthalmic research and clinical innovation.

🌍 Research Skills On Medicine

Wentao Han possesses a diverse set of research skills that bridge molecular biology, clinical medicine, and artificial intelligence applications in ophthalmology. His expertise includes conducting systematic reviews, meta-analyses, and experimental research on diabetic retinopathy and dry eye syndrome. He is proficient in bioinformatics tools for gene analysis and biomarker identification, which he applies to precision medicine. Han is skilled in laboratory techniques such as immunohistochemistry, cell culture, and animal models for ocular disease studies. His ability to integrate AI and machine learning into medical research has led to innovative predictive models for disease diagnosis. Additionally, his work in gene therapy for corneal and meibomian gland dysfunction highlights his translational research capabilities. Han’s interdisciplinary approach allows him to explore novel therapeutic targets, making significant contributions to evidence-based medicine. His research aims to improve diagnostic accuracy and therapeutic interventions in ophthalmic and metabolic disorders.

📖 Publication Top Notes

  • Research Progress and Potential Applications of Spermidine in Ocular Diseases
  • Machine Learning Prediction Models for Gestational Diabetes Mellitus: Meta-analysis
    • Authors: Zheqing Zhang, Luqian Yang, Wentao Han, Yaoyu Wu, Linhui Zhang, Chun Gao, Kui Jiang, Yun Liu, Huiqun Wu
    • Citation: Journal of Medical Internet Research, 2022-03-16
    • Year: 2022
    • DOI: 10.2196/26634
  • Genome Analysis and Identification of Key Pathway in Visceral Adipose Tissue from Obesity-Related Diabetes
    • Authors: Wentao Han
    • Citation: Proceedings of the 2021 International Conference on Bioinformatics and Intelligent Computing, 2021-01-22
    • Year: 2021
    • DOI: 10.1145/3448748.3448757
  • Machine Learning Prediction Models for Gestational Diabetes Mellitus: Meta-analysis (Preprint)
    • Authors: Zheqing Zhang, Luqian Yang, Wentao Han, Yaoyu Wu, Linhui Zhang, Chun Gao, Kui Jiang, Yun Liu, Huiqun Wu
    • Citation: Preprint, 2020-12-19
    • Year: 2020
    • DOI: 10.2196/preprints.26634
  • Construction of a Knowledge Graph for Diabetes Complications from Expert-Reviewed Clinical Evidences
    • Authors: Wentao Han
    • Citation: Computer Assisted Surgery (Abingdon, England), 2020-11-25
    • Year: 2020
    • DOI: 10.1080/24699322.2020.1850866
    • PMID: 33275462
  • Association Between Retinol Binding Protein 4 and Diabetic Retinopathy Among Type 2 Diabetic Patients: A Meta-analysis
    • Authors: Wentao Han, Huagen Wei, Weizheng Kong, Jing Wang, Luqian Yang, Huiqun Wu
    • Citation: Acta Diabetologica, 2020-10
    • Year: 2020
    • DOI: 10.1007/s00592-020-01535-3